AP Biosciences, Inc. (6945) Stock Price & Analysis
6945 Stock Chart & Stats
- Day’s Range
- TWD 104.50 - TWD 118.00
- 52-Week Range
- TWD 86.10 - TWD 236.00
- Previous Close
- TWD 116.00
- Volume
- N/A
- Average Volume (3M)
- 349.08K
- Market Cap
- TWD 10.92B
- Enterprise Value
- TWD 6.86B
- Total Cash (Recent Filing)
- TWD 2.19B
- Total Debt (Recent Filing)
- TWD 53.73M
- Price to Earnings (P/E)
- ―
- Beta
- 0.77
- Next Earnings
- Dec 21, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
6945 FAQ
What was AP Biosciences, Inc.’s price range in the past 12 months?
What is AP Biosciences, Inc.’s market cap?
When is AP Biosciences, Inc.’s upcoming earnings report date?
How were AP Biosciences, Inc.’s earnings last quarter?
Is AP Biosciences, Inc. overvalued?
Does AP Biosciences, Inc. pay dividends?
What is AP Biosciences, Inc.’s EPS estimate?
How many shares outstanding does AP Biosciences, Inc. have?
What happened to AP Biosciences, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AP Biosciences, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
AP Biosciences, Inc.
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Jeng-Horng Her
- Employees
- 37
- Website
- www.apbioinc.com
- Address
- No. 508, Zhongxiao East Road, Taipei City, TP, 115011, TW
AP Biosciences, Inc. (6945) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 1 | 0 | 11 |

